We also found that ASPP2 could promote the gemcitabine induced cell apoptosis in pancreatic cancer cells, and knockdown ASPP2 can enable the phenotype of the cells to resistant for gemcitabine treatment. Here, TP53BP2 is linked to pancreatic neoplasm.